Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEXABRIX vs ISOVUE-370
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Intravascular administration for computed tomography (CT) imaging,Intrathecal administration for myelography (CT and conventional),Angiography (coronary, cerebral, peripheral, etc.),Intravenous urography,Left ventriculography,Arteriography,Other radiographic contrast procedures
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
Intravenous injection of 50-200 m L of Isovue-370 (iopamidol 76% solution, 370 mg I/m L) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 m L total volume.
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 m L/min); prolonged to up to 30 hours in severe renal impairment.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Not metabolized; eliminated unchanged via glomerular filtration.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
Negligible (<5%); no specific binding proteins
Minimal; approximately 1-5% bound to serum proteins (primarily albumin).
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Volume of distribution (Vd) is approximately 0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid (plasma and interstitial space).
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
Not applicable (administered intravascularly); bioavailability is 100% for intravenous and intra-arterial routes as it does not undergo first-pass metabolism.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
No specific dose adjustment guidelines exist for Isovue-370 in renal impairment; however, caution is advised. In patients with GFR < 30 m L/min/1.73m², use lowest necessary dose and ensure adequate hydration. Hemodialysis may remove contrast; post-procedure dialysis can be considered.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
No specific dose adjustment is required based on hepatic impairment; monitor renal function closely in patients with severe hepatic disease due to potential reduced clearance.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
Weight-based dosing: 1-2 m L/kg (3.7-7.4 mg I/kg) intravenously, not exceeding 3 m L/kg total dose. Adjusted based on imaging indication and patient factors; for CT, 1.5-2 m L/kg typical.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
Elderly patients may require lower doses due to age-related renal impairment and increased risk of contrast-induced nephropathy. Use the minimal effective dose and ensure adequate hydration. Individualize based on renal function.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
No FDA black box warning.
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
Risk of serious anaphylactic reactions; have emergency equipment available.,Acute renal toxicity, especially in patients with pre-existing renal impairment, diabetes, or dehydration.,Contrast-induced nephropathy; ensure adequate hydration.,Extravasation risk; monitor injection site.,Thyroid storm in patients with hyperthyroidism or thyroid nodules.,Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome).,Exacerbation of sickle cell disease.,Intrathecal use may cause neurotoxicity; avoid high doses.
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
History of hypersensitivity to iopamidol or other iodinated contrast agents.,Acute pancreatitis (for intrathecal use).,Intrathecal administration in patients with blood in CSF or increased intracranial pressure.,Anuria or severe renal impairment (relative).
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
No specific food restrictions are required for this contrast agent. Maintain adequate hydration before and after administration. No known food-drug interactions.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Iodinated contrast media, including iopamidol (ISOVUE-370), cross the placenta. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, due to potential fetal hypothyroidism from free iodide exposure, use in pregnancy only if clearly needed. First trimester: theoretical risk of fetal thyroid suppression; second and third trimesters: risk of neonatal hypothyroidism if high doses or repeated exposures. No documented congenital malformations in human data.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
Iopamidol is excreted into human breast milk in minimal amounts (estimated infant dose <0.01% of maternal dose). M/P ratio not available. Because of low oral bioavailability and rapid milk clearance, breastfeeding can be continued without interruption; some sources suggest discarding milk for 12-24 hours post-procedure as a precaution.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
No specific dose adjustment required for pregnancy based on pharmacokinetic changes. However, because of increased plasma volume and glomerular filtration rate in pregnancy, the elimination half-life may be slightly reduced. Use the lowest effective dose to minimize fetal iodide exposure. Adequate hydration is essential to prevent contrast-induced nephropathy.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
Pre-warm contrast to body temperature to reduce viscosity and patient discomfort. Assess renal function (e GFR >30 m L/min/1.73m²) prior to administration; use lowest possible dose in patients with renal impairment. Have emergency equipment available for hypersensitivity reactions. For intravascular use, ensure adequate hydration before and after procedure. In diabetic patients taking metformin, withhold metformin for 48 hours post-contrast and monitor renal function.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
Inform your doctor if you have a history of allergic reactions to contrast media, asthma, or allergies.,Drink plenty of fluids before and after the procedure to help protect your kidneys.,Report any symptoms such as hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you are diabetic and take metformin, ask your doctor about temporarily stopping it.,You may feel warmth or a metallic taste during injection; these sensations are temporary.,Notify your doctor if you are pregnant, nursing, or have kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEXABRIX vs ISOVUE-370, answered by our medical review team.
HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. ISOVUE-370 is a Contrast Media that works by Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEXABRIX and ISOVUE-370 depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. The standard adult dose of ISOVUE-370 is: Intravenous injection of 50-200 m L of Isovue-370 (iopamidol 76% solution, 370 mg I/m L) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 m L total volume.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HEXABRIX and ISOVUE-370 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. ISOVUE-370 is classified as Category C. Iodinated contrast media, including iopamidol (ISOVUE-370), cross the placenta. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, due t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.